Your browser doesn't support javascript.
loading
Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3.
Wolfe, Amy; Stimpson, Georgia; Ramsey, Danielle; Coratti, Giorgia; Dunaway Young, Sally; Mayhew, Anna; Pane, Marika; Rohwer, Annemarie; Muni Lofra, Robert; Duong, Tina; O'Reilly, Emer; Milev, Evelin; Civitello, Matthew; Sansone, Valeria A; D'Amico, Adele; Bertini, Enrico; Messina, Sonia; Bruno, Claudio; Albamonte, Emilio; Mazzone, Elena; Main, Marion; Montes, Jacqueline; Glanzman, Allan M; Zolkipli-Cunningham, Zarazuela; Pasternak, Amy; Marini-Bettolo, Chiara; Day, John W; Darras, Basil T; De Vivo, Darryl C; Baranello, Giovanni; Scoto, Mariacristina; Finkel, Richard S; Mercuri, Eugenio; Muntoni, Francesco.
Affiliation
  • Wolfe A; Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK.
  • Stimpson G; Evelina London Children's Hospital, Guys and St Thomas' NHS Foundation Trust, London, UK.
  • Ramsey D; National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, London, UK.
  • Coratti G; Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK.
  • Dunaway Young S; National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, London, UK.
  • Mayhew A; University of Suffolk, Ipswich, UK.
  • Pane M; Pediatric Neurology Unit, Catholic University, Rome, Italy.
  • Rohwer A; Centro Clinico Nemo, U.O.C. Neuropsichiatria Infantile Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Muni Lofra R; Stanford University, Palo Alto, USA.
  • Duong T; John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University, Integrated Laboratory Medicine, Newcastle Upon Tyne Hospitals NHS Foundation Trust, UK.
  • O'Reilly E; Pediatric Neurology Unit, Catholic University, Rome, Italy.
  • Milev E; Centro Clinico Nemo, U.O.C. Neuropsichiatria Infantile Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Civitello M; Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK.
  • Sansone VA; National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, London, UK.
  • D'Amico A; John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University, Integrated Laboratory Medicine, Newcastle Upon Tyne Hospitals NHS Foundation Trust, UK.
  • Bertini E; Stanford University, Palo Alto, USA.
  • Messina S; Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK.
  • Bruno C; National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, London, UK.
  • Albamonte E; Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK.
  • Mazzone E; National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, London, UK.
  • Main M; St. Jude Children's Research Hospital, Memphis, USA.
  • Montes J; Nemours Children's Hospital and University of Central Florida College of Medicine, Orlando, USA.
  • Glanzman AM; The NEMO Center in Milan, Neurorehabilitation Unit, University of Milan, ASST Niguarda Hospital, Milan, Italy.
  • Zolkipli-Cunningham Z; Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Pasternak A; Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Marini-Bettolo C; Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
  • Day JW; Center of Translational and Experimental Myology and Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, IRCCS Istituto Giannina Gaslini and University of Genoa, Genoa, Italy.
  • Darras BT; The NEMO Center in Milan, Neurorehabilitation Unit, University of Milan, ASST Niguarda Hospital, Milan, Italy.
  • De Vivo DC; Pediatric Neurology Unit, Catholic University, Rome, Italy.
  • Baranello G; Centro Clinico Nemo, U.O.C. Neuropsichiatria Infantile Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Scoto M; Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK.
  • Finkel RS; Columbia University Irving Medical Center, New York, USA.
  • Mercuri E; Children's Hospital of Philadelphia, Philadelphia, USA.
  • Muntoni F; Children's Hospital of Philadelphia, Philadelphia, USA.
J Neuromuscul Dis ; 11(3): 665-677, 2024.
Article in En | MEDLINE | ID: mdl-38427497
ABSTRACT

Background:

Spinal muscular atrophy (SMA) is a neuromuscular disorder characterised by progressive motor function decline. Motor function is assessed using several functional outcome measures including the Revised Hammersmith Scale (RHS).

Objective:

In this study, we present longitudinal trajectories for the RHS in an international cohort of 149 untreated paediatric SMA 2 and 3 patients (across 531 assessments collected between March 2015 and July 2019).

Methods:

We contextualise these trajectories using both the Hammersmith Functional Motor Scale Expanded (HFMSE) and Revised Upper Limb Module (RULM). At baseline, this cohort included 50% females and 15% of patients had undergone spinal fusion surgery. Patient trajectories were modelled using a natural cubic spline with age, sex, and random effects for each patient.

Results:

RHS and HFMSE scores show similar trends over time in this cohort not receiving disease modifying therapies. The results confirm the strong correlation between the RHS and RULM previously observed in SMA types 2 and 3a. Scoliosis surgery is associated with a reduction of 3 points in the RHS, 4.5 points in the HFMSE for the SMA 2 population, and a reduction of 11.8 points in the RHS, and 13.4 points in the HFMSE for the SMA 3a populations. When comparing the RHS and RULM, there is a lower correlation in the type 3a's than the type 2 patients. In the SMA 2 population, there is no significant difference between the sexes in either the RHS or HFMSE trajectories. There is no significant difference in the RULM trajectory in the SMA 2 or 3a participants by sex.

Conclusions:

This study demonstrates that the RHS could be used in conjunction with other functional measures such as the RULM to holistically detect SMA disease progression. This will assist with fully understanding changes that occur with treatments, further defining trajectories and therapy outcomes.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Spinal Muscular Atrophies of Childhood Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Language: En Journal: J Neuromuscul Dis Year: 2024 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Spinal Muscular Atrophies of Childhood Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Language: En Journal: J Neuromuscul Dis Year: 2024 Document type: Article Country of publication: